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Abstract (200 words) 
 
Objective: Taking adjuvant hormonal therapy for 5-10 years is recommended to prevent 
breast cancer recurrence in those with estrogen positive disease. Despite proven clinical 
efficacy many women do not take their hormonal therapy as prescribed. This study reports 
the development and initial validation of a questionnaire measuring the behavioural 
determinants of hormonal therapy medication taking behaviour (MTB) based on the 
Theoretical Domains Framework (TDF). 
 
Design: Women with Stage I-III breast cancer (N=223) completed the questionnaire based on 
the TDF. The TDF is an integrative framework consisting of 14 domains of behaviour change 
determinants to inform intervention design.   
 
Main outcome measures: Items were developed from previous research, in-depth patient 
interviews and consultation with health professionals. Confirmatory factor analysis (CFA) 
was undertaken to generate the model of best fit. 
 
Results: The final questionnaire consisted of 8 domains and CFA produced a reasonable fit 
(χ2(810)=942, p < 0.001; RMSEA = 0.03 ; CFI = 0.93 and WRMR=0.91) as well as internal 
consistency (r=0.16 to 0.64). There were adequate levels of discriminant validity for the 
majority of the domains.   
 
Conclusions: A TDF based measure of the behavioural determinants of MTB was developed. 
Further research is needed to confirm the reliability and validity of this measure.  
 
Key words: Theoretical Domains Framework, medication taking behaviour, breast cancer, 
adherence, hormonal therapy  
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Introduction 
Clinical guidelines recommend that women with hormone receptor positive breast cancer 
receive at least five, and up to 10, years of adjuvant hormonal therapy as a preventative 
measure for breast cancer recurrence and mortality. (Davies et al., 2011) However, despite the 
proven clinical efficacy of adjuvant hormonal therapy many women do not take their 
treatment as recommended. Reduced hormonal therapy exposure due to early treatment 
discontinuation (non-persistence) or failure to take the correct dosage at the prescribed 
frequency (non-adherence) is associated with an increased risk of early breast cancer 
recurrence and mortality.(Barron, Cahir, Sharp, & Bennett, 2013; Chirgwin et al., 2016; 
Hershman et al., 2011) Rates of non-persistence at 5 years range from 16% to 32% in clinical 
trials of hormonal treatment and between 31% and 73% in routine clinical settings, while 
prevalence of non-adherence ranges from 41% to 72%.(Barron, Connolly, Bennett, Feely, & 
Kennedy, 2007; Murphy, Bartholomew, Carpentier, Bluethmann, & Vernon, 2012)  
Despite the high prevalence of hormonal therapy non-persistence and non-adherence little is 
known about the risk factors associated with hormonal therapy medication taking behaviour 
(MTB). Recent systematic reviews have identified follow-up care with a general practitioner 
(compared to follow-up by an oncologist) and experience of treatment side-effects as largely 
negatively associated with persistence, while taking more medications at baseline has been 
positively associated with persistence. (Cahir, Guinan, Dombrowski, Sharp & Bennett, 2015; 
Murphy et al., 2012) These reviews highlighted a critical need to identify potentially 
modifiable determinants that influence hormonal therapy MTB in order to develop 
behavioural interventions to improve this behaviour. 
The Theoretical Domains Framework (TDF) is an integrative framework of multiple theories 
of behaviour change designed to assess complex behavioural issues such as MTB and inform 
intervention design.(Cane, O’Connor, & Michie, 2012; Michie et al., 2005; Michie, Johnston, 
Francis, Hardeman, & Eccles, 2008) The TDF has recently been validated and refined to 
include 14 domains of potential behavioural determinants. (Cane et al., 2012).  A number of 
studies have applied the TDF to assess potential behavioural determinants across a range of 
clinical settings and populations. (Cahir et al., 2014; Penn, Dombrowski, Sniehotta &White, 
2013; Dombrowski, et al., 2012; McSherry et al., 2012) However, the majority of these 
studies have used qualitative interviews which limit the generalisability of the findings. 
(Francis, O’Connor & Curran, 2012) A small number of TDF based questionnaires have been 
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developed, which have assessed the behavioural determinants of, for example, smoking 
cessation in dental healthcare (Amemori, Michie, Korhonen, Murtomaa, & Kinnunen, 2011) 
and maternal care (Beenstock et al., 2012), patient safety behaviours in hospital (Taylor, 
Parveen, Robins, Slater, & Lawton, 2013) and healthcare professionals implementation 
behaviour. (Huijg et al., 2014) The TDF has not been used to develop a questionnaire 
measuring the behavioural determinants of MTB.   
The aim of the current study is to develop a questionnaire measuring the behavioural 
determinants of hormonal therapy MTB based on the 14 domain version of the TDF (Cane et 
al., 2012) and to test the psychometric properties of this questionnaire in a sample of women 
with stage I-III breast cancer prescribed hormonal therapy. 
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Methods 
Development of the TDF questionnaire measuring the modifiable determinants of hormonal 
therapy MTB 
The TDF questionnaire items were developed from previous research by the research team 
including; (i) a systematic review of the modifiable influences on adjuvant hormonal therapy 
MTB (Cahir et al., 2015); (ii) in depth interviews with women with stage I-III breast cancer 
prescribed adjuvant hormonal therapy (Cahir et al., 2014) and; (iii) by review and 
consultation within the research team.  
 
The systematic review identified potentially modifiable determinants of hormonal therapy 
MTB in women with breast cancer in routine clinical settings and mapped these determinants 
to the 14 domains of the TDF.  The 14 TDF domains are; Knowledge; Skills; Memory, 
Attention and Decision Processes; Behavioural Regulation; Social/professional role and 
identity; Beliefs about Capabilities; Optimism; Beliefs about Consequences; Intentions; 
Goals; Reinforcement; Emotion; Environmental Context and Resources; and Social 
Influences. Each domain is defined as a group of related theoretical constructs (where 
constructs are defined as component part of theories, such as ‘attitude’, ‘self-efficacy’, 
‘anxiety’). For example, the domain Social Influences includes the constructs social support, 
group norms, social comparisons and several others and the constructs are grouped together 
to represent the influences of people on others’ behaviours. (Francis et al., 2012; Michie et 
al., 2005) In meta-analysis three domains (Beliefs about Capabilities, Social Influences, and 
Behaviour Regulation) were found to be associated with hormonal therapy MTB. However 
several domains associated with MTB in other disease groups including Beliefs about 
Consequences, Intentions, Goals, Social Identity, Emotion and Knowledge which have been 
reported to influence MTB in other disease groups were not examined.(Cahir et al., 2015) 
 
In-depth interviews were conducted with thirty-one women (14 adherent and persistent, 7 
non-adherent and persistent, 10 non-persistent) with stage I-III breast cancer prescribed 
adjuvant hormonal therapy at two cancer centres in Ireland with the TDF informing the 
analysis framework. Key enablers for adherent and persistent women, based upon pre-
specified criteria, were identified within the domain Beliefs about Consequences (breast 
cancer recurrence), Intentions and Goals (high-priority), Beliefs about Capabilities (side-
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effects) and Behaviour Regulation (managing medication). Adherent and persistent women 
strongly believed in the efficacy and necessity of their therapy, were highly motivated and 
adapted a wide range of coping techniques and support networks to enable them to take their 
treatment and manage side-effects. Key barriers, based upon pre-specified criteria, were 
identified within the domain Behaviour Regulation (no routine), Memory, Attention and 
Decision Processes (forgetting) and Environmental Context and Resources (stressors) for 
non-adherent and persistent women and Intentions and Goals (quality of life), Behaviour 
Regulation (temporal self-regulation), Reinforcement, Beliefs about Consequences (non-
necessity) and Social Influences (clinical support) for non-persistent women. Non-adherence 
was associated with inadequate medication management techniques and non-persistence was 
associated with a strong distrust of medication and the health care system, a lack of perceived 
need for treatment and a preference for a good quality of life with little concern or thought 
given to future outcomes.(Cahir et al., 2014)  
 
The findings from both the systematic review and qualitative interviews were combined and 
9 domains and their related constructs were identified as key domains for the MTB 
questionnaire.(Cahir et al., 2014; Cahir et al., 2015) (Appendix I) The refined framework for 
the MTB questionnaire, based on previous research, did not include the domain Skills as the 
only skill proficiency required was to swallow a tablet daily. The domains Intentions and 
Goals and Reinforcement were included as one domain (Intentions and Goals and 
Reinforcement) in line with the original 12 domain TDF (Intentions and Goals) and 
Reinforcement was included based on the qualitative interviews where goal conflict and goal 
facilitation and reinforcement were shown to be contingent on each other. (Cahir et al., 2014; 
Michie et al., 2005) Within the qualitative interviews we found that women who were non-
persistent with their hormonal therapy wanted to be finished with their treatment (Intentions 
and Goals) and felt their treatment conflicted with their everyday life and plans (goal 
conflict). Many women reported an improvement in their quality of life and feeling “back to 
myself” once they ceased their treatment (Reinforcement).(Cahir et al., 2014)  
 
The domain Optimism was renamed Personality and extended to include other personality 
constructs, such as resilience which had emerged from the qualitative interviews.(Cahir et al., 
2014) The domain Personality was included with the domain Beliefs about Capabilities as 
only one key construct “resilience” was relevant to MTB within the domain Personality and 
“resilience” was associated with “coping skills” within the domain Beliefs about Capabilities. 
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This is in line with the original 12 domain TDF where the domain Optimism was included in 
the domain Beliefs about Capabilities. (Michie et al., 2005) Similarly, the domain Emotion 
was included with the domain Beliefs about Consequences as only one key construct “worry 
about breast cancer recurrence” was relevant to MTB within the domain Emotion and this 
was associated with outcome expectancies in the domain Beliefs about Consequences.  
 
Potential individual validated scales for each construct within each domain were identified 
from the systematic review on potentially modifiable determinants of hormonal therapy MTB 
and the broader literature on MTB across other disease groups e.g. action planning, coping 
planning within the domain Behaviour Regulation.(Cahir et al., 2015) The identified 
individual scales for each construct were reviewed by a health psychologist (SD) and 
discussed with the broader research team (CC, LS, KB) and a consensus was reached on the 
measures for each construct. The consensus on the individual scales was informed by the 
academic literature on the scales, the definition of the constructs and domains as formulated 
by Michie et al. (Michie et al., 2005) and the specific constructs and domains that emerged 
from the interviews with women with stage I-III breast cancer prescribed hormonal therapy. 
(Cahir et al., 2014) For example, the domain Beliefs about Consequences and the construct 
‘utility of adhering’ is measured by the perceived utility of adhering (efficacy and benefits vs. 
costs of adhering) subscale of the Adherence Determinants Questionnaire (Appendix I). 
(DiMatteo et al., 1993) For some domains and their constructs (Knowledge- sources of 
knowledge, Beliefs about Consequences-outcome expectancies, Goals- Perceived 
reinforcement and goal conflict facilitation) new questions were developed from the 
interview data where there was a lack of relevant measures in the literature (Appendix I). 
(Cahir et al., 2014) For other domains and their constructs measures were adapted from the 
literature. For example a scale was developed using the health action process approach 
(HAPA) for the constructs coping self-efficacy and maintenance self-efficacy within the 
domain Beliefs about Capabilities. (Schwarzer, Lippke, & Luszczynska, 2011) (Appendix I) 
 
Participants  
 
Eligible participants were women aged between 18 and 80 years with a diagnosis of stage I-
III, oestrogen (ER) or progesterone (PR) receptor positive breast cancer diagnosed 2012-
2014, who had received tumour directed surgery and had subsequently filled at least one 
prescription for oral hormonal therapy (selective estrogen receptor modulator, SERM; 
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aromatase inhibitor, AI) within one year of breast cancer diagnosis. Participants were 
identified from St James’s Hospital Oncology database which contains detailed demographic 
and clinical information for all incident breast cancer diagnosed in St James’s Hospital 
Dublin, Ireland. Eligible participants were invited, by post, by their oncologist to take part in 
the study. Ethical approval was obtained from the Hospital Research Ethics Board, and all 
participants provided informed consent to participate. 
 
Procedure 
 
Participants were sent the questionnaire booklet by post for self-completion with a stamp 
addressed envelope. Those who had not returned a questionnaire were sent one reminder 
letter to complete the questionnaire 2-3 weeks after the initial mailing. The questionnaire 
consisted of sociodemographic questions, questions and validated scales for measuring the 9 
domains and their related constructs and questions relating to participants current hormonal 
therapy MTB. The hormonal therapy MTB questions asked participants whether or not they 
were; (i) currently taking their hormonal therapy on a regular basis (adherent and persistent) 
or; (ii) taking their hormonal therapy but regularly missing doses (non-adherent and 
persistent) or; (iii) had stopped taking their hormonal therapy (non-persistence) or; (iv) had 
never taken their hormonal therapy (non-initiators).  Participants who had stopped taking 
their hormonal therapy were also asked how long ago they stopped taking their hormonal 
therapy and who made the decision to stop taking their hormonal therapy e.g. themselves or 
their oncologist or doctor or both themselves and their oncologist or doctor. The 
questionnaire also included the Voils self-report measure of the extent of non-adherence 
(Voils et al., 2012). 
 
Statistical analysis 
 
Confirmatory factor analysis (CFA) was used to examine whether the items measuring the 
behavioural determinants of hormonal therapy MTB were a good fit to the TDF.  CFA was 
considered appropriate to test the theoretical framework (TDF) and to establish the initial 
construct validity of the questionnaire and remove unnecessary or deficient items. Sample 
size guidance indicated that 200 to 300 participants would be adequate for CFA analysis. 
(Bryant & Yarnold, 1995).  The data was screened and descriptive statistics were examined 
for all items, prior to data analysis including measures of central tendency, variability and 
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dispersion (skew, kurtosis) using Stata Version 14 (Stata Corporation, College Station, TX, 
USA). 
 
CFA was used to test the 9 factor model using weighted least square estimates (WLSMV). 
(Yu & Muthen, 2002) WLSMV is a robust estimator which does not assume normally 
distributed variables and provides the best option for modelling categorical or ordered data 
(Yu & Muthen, 2002). The guidelines for testing the model fit included; (i) a root mean 
square error of approximation (RMSEA) < 0.06 and; (ii) a comparative fit index (CFI) > 0.90 
and;(iii) the weighted root mean square residual (WRMR)<1.0. (Hooper, Coughlan, & 
Mullen, 2008; Yu & Muthén, 2002) Post-hoc analysisa was used to improve the model fit by 
inspecting modification indices (MIs), standardised residuals (SRs) and by assessing each 
constructs and related items within the context of the TDF. (Byrne, 2011; Hu & Bentler, 
1999) Inter-item correlations were used to test for internal consistency, with values above 
0.15 to 0.50 being the optimal range. (Clark & Watson, 1995)  The total score or subscale 
score for validated scales which measured particular constructs within a domain were used to 
calculate inter-item correlations.  Discriminant validity was assessed using Fornell and 
Larkner’s tests. Fornell & Larkner, 1981) The CFA analysis was undertaken using Mplus 
Version 7.31. 
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Results 
Descriptive statistics 
In total 223 women with stage I-III breast cancer and prescribed hormonal therapy completed 
the questionnaire on MTB (response rate= 61% , N=367 eligible participants). The average 
age was 61 years (SD=13.9) and 118 women (54.6%) were married. Sixty-five women 
(29.7%) had third level education and 60 women (28.4%) were currently employed outside of 
the home. Missing value analysis indicated that the data was missing at random (< 7% 
missing data across individual measures) and data was imputed using weighted least squares 
estimation. (Asparouhov & Muthén, 2010) 
One hundred and ninety-three women (88.5%) reported being both adherent and persistent 
with their hormonal therapy since commencing treatment; 12 women (5.5%) reported missing 
doses on a regular basis (non-adherent and persistent) and 13 women (6.0%) reported that 
they had stopped taking their hormonal therapy (non-persistent). No women reported never 
initiating their treatment. Non-adherent and persistent women and non-persistent women had 
significantly higher self-reported non-adherence scores (Voils scale) compared to adherent 
and persistent women (F(2,196) = 4.72, p = 0.01).(Table 1). 
Confirmatory factor analysis 
The initial CFA including the 9 domains showed that the data did not fit the model 
adequately (χ2(1,559)=2107, p<0.001; RMSEA=0.04; CFI=0.73 and WRMR=1.25). Post-hoc 
analysis was undertaken and the individual items and scales within each of the 9 domains and 
their constructs were examined. The domains Memory, Attention and Decision Processes and 
Environmental Context and Resources were highly correlated (>0.85). The domain Memory, 
Attention and Decision Processes was measuring any difficulties women experienced in 
remembering to take their hormonal therapy and the domain Environmental Context and 
Resources was measuring whether or not women forget to take their treatment when traveling 
or when there is interference with their normal routine. These two domains were incorporated 
into one domain Memory, Attention, Decision Processes and Environment for MTB.  
The measure of medication side-effect coping skills (SECope) was removed from the domain 
Beliefs about Capabilities and the Time Perspective Questionnaire (TPQ) was removed from 
the domain Behaviour Regulation. These measures had coefficients (R-Squared) <0.20  and 
large standardised residuals (> +/-2.58) which is an indication of a high level of error. 
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(Hooper et al., 2008) Questions relating to the decision making process about taking 
hormonal therapy with the patient’s oncologist and awareness of hormonal therapy side-
effects were removed from the domain Social Identity as these items also loaded onto other 
domains such as Knowledge and Behaviour Regulation. The domain Social Identity retained 
items related to the role of the oncology-patient relationship only. Within some domains such 
as Beliefs about Capabilities, subscales such as action self-efficacy scale, maintenance self-
efficacy scale and recovery self-efficacy error terms were allowed to covary as all 3 subscales 
were measuring the construct self-efficacy. The revised model consisting of 8 domains was 
found to fit the data satisfactorily (χ2(810)=942, p<0.001; RMSEA=0.03; CFI=0.93 and 
WRMR=0.91). The descriptive statistics for each item within each domain post CFA are 
presented in Table 2. 
Internal consistency 
The average inter item correlations (r) for each domain ranged from 0.16 to 0.64 with the 
domains Knowledge, Social Influences, Beliefs about Capabilities, Beliefs about 
Consequences, Behaviour Regulation and Memory, Attention, Decision Processes and 
Environment  demonstrating adequate levels (r > 0.15 and r < 0.50) of internal consistency 
(Table 2). 
Discriminant validity 
Six domains were found to display discriminant validity according to Fornell and Larkner 
(1981) suggesting that these domains measure a distinct construct. The scales within the 
domain Beliefs about Capabilities shared variance with the domain Beliefs about 
Consequences. 
  
12 
 
Discussion  
A questionnaire measuring the behavioural determinants of adjuvant hormonal therapy MTB 
was developed based on the TDF and was tested in a sample of women with stage I-III breast 
cancer prescribed hormonal therapy. The proposed structure of the TDF was tested using 
CFA and the questionnaire demonstrated good psychometric properties, with the majority of 
domains showing good internal consistency reliability and discriminant validity.   
This is the first study to develop a measure of the behavioural determinants of hormonal 
therapy MTB based on the TDF. MTB has been shown to be influenced by multiple 
determinants including patient related factors and health care provider and health care system 
related factors (e.g. quality of health care provider-patient communication) (Kardas, Lewek, 
& Matyjaszczyk, 2013) The application of the TDF enabled the development of a coherent 
and comprehensive measure of the behavioural determinants of MTB.  Existing models of 
MTB such as social cognition models or self-regulatory models which emphasise the 
importance of patient beliefs about their illness and treatment and ability to follow treatment 
advice, are not as comprehensive and do not include automatic processes such as habit 
formation which determine MTB or consider the broader health care influences. (Jackson, 
Eliasson, Barber, & Weinman, 2014)  
Eight of the 14 domains within the framework were determined relevant to the questionnaire 
measuring the behavioural determinants of hormonal therapy MTB. However only one 
domain Skills was excluded from the framework. The 8 domains comprised of a combination 
of domains from the framework e.g. 3 domains (Intention, Goals, Reinforcement) were 
combined into one domain (Intentions and Goals and Reinforcement). The adjustments to the 
framework were made to adequately reflect and account for the relationship between the 
constructs within the individual domains, which were shown to determine MTB and were 
based on previous research and the current CFA findings. (Cahir et al., 2014) Huijg et 
al.,(2014) also found that items measuring the domains Reinforcement and Goals measured a 
combination of domains in a generic questionnaire of behavioural determinants and that these 
domains may not be able to be discriminately measured. They also found that items 
measuring general feelings (e.g. stress) were able to discriminately assess the domain 
Emotion while emotions relating to performing a specific behaviour (e.g. affect) were not 
able to. In the current study emotions relating to the behaviour of taking/not taking hormonal 
therapy were determined to be measured by the domain Beliefs about Consequences.   
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There are a number of limitations to this study which need to be taken into consideration 
when interpreting the results. The sample size was adequate but given the number of 
variables measured within each domain a larger sample would provide increased confidence 
in the reliability and validity of the measure.  Women were sampled from one hospital only 
and the modifications to the TDF need to be evaluated across the general breast cancer 
population. Further research is also needed to confirm the reliability and validity of the 
questionnaire. The domains Beliefs about Capabilities and Beliefs about Consequences did 
not have adequate discriminant validity. The domain Beliefs about Consequences included a 
larger number of constructs than the other domains and some of these constructs may also be 
relevant to other domains.  Hormonal therapy treatment is associated with a number of side-
effects, including arthralgia, hot flashes and gynecologic symptoms which can range in 
severity.(Guth, Myrick, Schotzau, Kilic, & Schmid, 2011) The domain Beliefs about 
Capabilities did not sufficiently measure women’s ability to cope with hormonal therapy 
side-effects and this measure of capability needs to be included in future studies. The domain 
Intentions, Goals and Reinforcement did not have adequate internal consistency and some 
items may be highly redundant with each other and need to be re-evaluated and tested.  
Hence, although the application of the TDF enables a comprehensive measure of the 
behavioural determinants of MTB, the number of domains and underlying constructs need to 
be assessed by a large amount of items and existing scales were not available for some unique 
aspects of MTB.  The selection of constructs within each domain was based on previous 
research and expert guidance but these constructs may not in fact be highly relevant to 
hormonal therapy MTB or may not have been effectively measured leading to decreased 
validity of the measurement of some domains. Equally some constructs which were excluded 
based on previous research may in fact be relevant. Further work is required to establish 
which constructs are essential for determining MTB and adequately measure the given 
domains.  
One of limitations of the TDF in its current form is that it is a descriptive framework and it 
does not specify relationships between domains. (Francis et al., 2012)  It is feasible that the 
lack of discriminant validity for the domains Beliefs about Consequences and Beliefs about 
Capabilities is a result of a relationship between the determinants of MTB within these 
domains. The Health Belief Model has previously been applied as a framework to explain 
MTB, with beliefs about disease severity, personal susceptibility to recurrence, efficacy of 
treatment, self-efficacy, barriers to treatment and cues to action suggested as significant 
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influences on health behaviours and some of these determinants are measured by the domains 
Beliefs about Consequences and Beliefs about Capabilities.(DiMatteo, Haskard, & Williams, 
2007) Within the TDF the boundaries between the various domains require more clarification 
and precision. Future research should not only establish the essential constructs for 
determining MTB, but should also identify and model the appropriate theories that are 
relevant to hormonal therapy MTB and assess if the identified constructs and domains are 
related to each other, prior to intervention design. 
This study has also not established the criterion validity of the questionnaire on hormonal 
therapy MTB. Women in the sample were asked to self-report their hormonal therapy MTB 
and there was some indication of differences across domains for the different MTB groups 
but the numbers within each group were too small for formal analysis. A larger scale study of 
women with stage I-III breast cancer prescribed hormonal therapy is currently underway to 
establish criterion validity and this will also identify the key domains and determinants of 
hormonal therapy MTB and assess potential relationships between them. This will enable the 
development of a more refined and effective questionnaire that can be used in clinical 
practice. Prospective cohort studies are also needed to investigate the predictive validity of 
the questionnaire and the extent each domain can predict future hormonal therapy MTB.  
Notwithstanding the further work required to improve the reliability, validity and 
generalisability of the questionnaire, a theoretical based measure of the behavioural 
determinants of hormonal therapy MTB has been developed and can be used as a tool for 
informing the development of interventions to improve MTB.  A recent Cochrane review of 
MTB interventions concluded that to date only a minority of published interventions have 
improved MTB or enhanced patient outcomes.(Nieuwlaat et al., 2014) In general, reviews of 
MTB interventions have reported similar findings; with some intervention components being 
potentially effective, but small sample sizes and suboptimal methodology often preventing 
strong conclusions and most studies have been developed without a thorough theoretical 
understanding of the factors that influence MTB.(van Dulmen et al., 2007) The application of 
the TDF enables a comprehensive assessment of the determinants of hormonal therapy MTB 
and it also specifies how to target particular theoretical domains through a number of 
effective behaviour change techniques (BCTs).(Cane, Richardson, Johnston, Ladha, & 
Michie, 2015) Previous theories and frameworks used in MTB have identified a range of 
potential determinants but they have not specified how to change MTB. Theoretically based 
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tailored interventions using BCTs may be more effective at improving hormonal therapy 
MTB. 
The focus of the current study has been on hormonal therapy MTB in women with stage I-III 
breast cancer but the measures within this questionnaire may be relevant to MTB in other 
medical conditions and disease groups. The World Health Organisation has reported that on 
average 30-50% of patients prescribed medications for chronic illnesses do not adhere to their 
prescribed medication regimen.(Sabaté, 2003) Patient beliefs and behaviour processes such as 
habit formation are likely to characterise MTB in all medical conditions and treatments, with 
some specific determinants of MTB being significant for particular conditions or treatments 
e.g. HIV and mental illness.(Horne & Weinman, 1999)  
Conclusion 
This study describes the development and initial validation of a TDF based questionnaire 
measuring the behavioural determinants of hormonal therapy MTB. Initial results indicate 
that the measure is reliable and valid and can be used to measure determinants of hormonal 
therapy MTB in clinical practice. Further research is needed to determine and improve the 
psychometric properties of the questionnaire and to fully understand its strengths and 
limitations. In addition, more research is needed to establish if the questionnaire is valid for 
MTB in other disease groups and in other settings. This will increase knowledge about the 
factors related to MTB and may help establish which techniques are most effective at 
addressing each of the components of MTB, resulting in more effective and pragmatic MTB 
interventions. 
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Endnote 
 
aThe MIs (>10) were provided by Mplus for all parameters constrained to zero and indicate 
when an item may cross load or load onto a different factor. The standardised residual matrix 
items that are either under or over-predicted by the model for which values >+/- 2.58 are 
considered to be large.(Brown, 2015) 
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Appendix I 
 
Domain Construct  Measurement 
Knowledge  Overall knowledge about hormonal therapy 
 
1 question developed from 
qualitative interviews 
 Sources of knowledge/information 1 question developed from 
qualitative interviews 
 Satisfaction with information about hormonal 
therapy 
Satisfaction with information 
about medicine scale (SIMS)- 
Action and Usage subscale and 
Potential problems scale1 
Social Influences Support and Barriers  Adherence Determinants 
Questionnaire 
Support/Barriers subscale - 
adapted and reduced to 3 
questions2 
 Social norms 
 
Injunctive norms –3 questions 
adapted from Trinh et al. (2014) 
analysis of motivational 
outcomes in breast cancer 
survivors from the Theory of 
Planned Behaviour3 
  Descriptive norms –2 questions 
adapted from Trinh et al. (2014) 
analysis of motivational 
outcomes in breast cancer 
survivors from the Theory of 
Planned Behaviour3 
Social Identity Support from oncologist  Patient-Centred Care Items from 
National Initiative on Cancer 
Care Quality Breast Cancer 
Patient Survey- 1 question4 
 Support from oncology services - one main point 
of contact/support 
Patient-Centred Care Items from 
National Initiative on Cancer 
Care Quality Breast Cancer 
Patient Survey-1 question4 
 Relationship with oncologist- listening Patient-Centred Care Items from 
National Initiative on Cancer 
Care Quality Breast Cancer 
Patient Survey- 1 question4 
 Relationship with oncologist- understanding Patient-Centred Care Items from 
National Initiative on Cancer 
Care Quality Breast Cancer 
Patient Survey- 1 question4 
 Relationship with oncologist- respect Patient-Centred Care Items from 
National Initiative on Cancer 
Care Quality Breast Cancer 
Patient Survey- 1 question4 
 Relationship with oncologist- time Patient-Centred Care Items from 
National Initiative on Cancer 
Care Quality Breast Cancer 
Patient Survey- 1 question4 
Beliefs about 
Capabilities 
Action self-efficacy 3 questions based on the health 
action process approach (HAPA)5 
 Maintenance self-efficacy 3 questions based on the health 
action process approach (HAPA)5 
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Domain Construct  Measurement 
 Recovery self-efficacy  3 questions based on the health 
action process approach (HAPA)5 
 Strategies for coping with medication side-
effects 
The 20-item measure assesses 
strategies for coping with 
treatment side effects, and 
includes scales of Positive 
Emotion Focused Coping, Social 
Support Seeking, Nonadherence, 
Information Seeking, and Taking 
Side Effect Medications6 
Personality (included 
with Beliefs about 
Capabilities) 
Resilience  Brief Resilience Scale7 
 
Beliefs about 
Consequences 
Perceived severity of breast cancer 
 
Adherence Determinants 
Questionnaire-  
Perceived severity of disease 
subscale2 
 Perceived susceptibility to breast cancer Adherence Determinants 
Questionnaire- Perceived 
susceptibility to disease subscale2 
 Perceived utility of adhering to hormonal therapy Adherence Determinants 
Questionnaire-  
Perceived utility of adhering 
subscale2 
 Illness perceptions Brief Illness Perceptions Scale-  
Consequences subscale- adapted 
to reference breast cancer 
recurrence8 
 Beliefs about hormonal therapy- necessity and 
concerns 
Beliefs about Medicines 
Questionnaire (BMQ)- necessity 
and concerns subscales9 
 Outcome expectancies 
 
5 questions developed from 
qualitative interviews about 
outcome expectancies in relation 
to taking or not taking hormonal 
therapy 
  4 questions adapted from Phillips 
et al.(2013) perceived risk of 
cancer recurrence in breast cancer 
survivors (2 questions in relation 
to taking hormonal therapy and 2 
questions in relation to not taking 
hormonal therapy)10 
Emotion (included with 
Beliefs about 
Consequences) 
Concern about breast cancer recurrence Breast cancer recurrence worry 
scale11 
 
Intentions Intention to take hormonal therapy as prescribed Adherence Determinants 
Questionnaire-  
Intentions to adhere subscale2 
Goals (included with 
Intentions) 
Autonomous motivation Treatment Self-regulation 
Questionnaire- 6 questions 
adapted for hormonal therapy 
MTB12 
 Introjected regulation Treatment Self-regulation 
Questionnaire- 2 questions 
adapted for hormonal therapy 
MTB12 
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Domain Construct  Measurement 
 External Regulation Treatment Self-regulation 
Questionnaire- 4 questions 
adapted for hormonal therapy 
MTB12 
 Amotivation Treatment Self-regulation 
Questionnaire- 3 questions 
adapted for hormonal therapy 
MTB12 
 Goal conflict 
 
Adapted Illness Intrusiveness 
Ratings- Physical Well-Being (2 
questions), Work and Finances (2 
questions), Marital, Sexual and 
Family Relations (3 questions), 
Recreation and Social Relations 
(3 questions), Other aspects of 
life (3 questions)13 
 Temporal Self-Regulation 
 
Time perspective questionnaire14 
Reinforcement 
(included with 
Intentions and Goals) 
Perceived reinforcement and goal conflict and 
facilitation 
 
4 questions developed from 
qualitative interviews  
Behaviour Regulation   
 
Action planning 4 questions adapted from 
Sniehotta et al (2005) action 
planning for long-term lifestyle 
change15 
 Coping planning  4 questions adapted from 
Sniehotta et al (2005) coping 
planning for long-term lifestyle 
change15 
 Action control Action control- 6 questions- 
Awareness of standards (2 
questions), self-monitoring (2 
questions) and self-regulatory 
efforts (2 questions)16 
Memory, Attention, 
Decision Making 
Forgetting/difficulties remembering to take 
hormonal therapy 
Morisky adherence scale – first 
two items (MMAS-4)17 
 Forgetting/difficulties remembering to get 
prescription refilled  
1 question developed from 
qualitative interviews 
 Forgetting/difficulties recalling medication usage 1 question developed from 
qualitative interviews 
 Habit strength- history of repetition, automaticity 
(lack of control and awareness, efficiency) 
Self-report Behavioural 
Automaticity Index (SRBAI)18 
Environmental Context 
and Resources  
Environmental Context- forget when travelling 
or leaving home  
1 question developed from 
qualitative interviews 
 Environmental Context- forget when 
interruptions to normal routine  
1 question developed from 
qualitative interviews 
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(SIMS): a new measurement tool for audit and research. Quality in Health Care : QHC, 10(3), 135–140. 
http://doi.org/10.1136/qhc.0100135. 
2 DiMatteo, M. R., Hays, R. D., Gritz, E. R., Bastani, R., Crane, L., Elashoff, R., . . . Marcus, A. (1993). Patient 
adherence to cancer control regimens: Scale development and initial validation. Psychological Assessment, 5(1), 
102-112. doi: 10.1037/1040-3590.5.1.102 
26 
 
3 Trinh, L., Mutrie, N., Campbell, A. M., Crawford, J. J., & Courneya, K. S. (2014). Effects of supervised 
exercise on motivational outcomes in breast cancer survivors at 5-year follow-up. European Journal of 
Oncology Nursing, 18(6), 557-563. DOI: 10.1016/j.ejon.2014.07.004 
4 Kahn, K L., Schneider, E C., Malin, J L., Adams, J L., Epstein, A M. (2007) Patient Centered Experiences in 
Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use. Medical Care, 45(5),431-439 
5 Schwarzer, R., Lippke, S., & Luszczynska, A. (2011). Mechanisms of health behavior change in persons with 
chronic illness or disability: The Health Action Process Approach (HAPA). Rehabilitation Psychology, 56(3), 
161-170. doi: 10.1037/a0024509 
6 Mallory O. J., Torsten B. (2007) Coping with HIV treatment side effects: Conceptualization, measurement, and 
linkages. AIDS Behaviour. 11(4): 575–585. 
7 Smith BW, Dalen J, Wiggins K, Tooley E, Christopher P, Bernard J (2008) The Brief Resilience Scale: 
Assessing the Ability to Bounce Back. International Journal of Behavioral Medicine, 15: 194–200 
8Broadbent E, Petrie K.J., Main J., Weinman J (2006) The Brief Illness Perception Questionnaire.  Journal of 
Psychosomatic Research 60,  631– 637 
9 Horne R, Weinman J (1999) Patients' beliefs about prescribed medicines and their role in adherence to 
treatment in chronic physical illness. J Psychosom Res 47(6):555–567 
10 Phillips KM, McGinty HL, Gonzalez BD, Jim HS, Small BJ, Minton S,… Jacobsen PB.(2013) Factors 
associated with breast cancer worry 3 years after completion of adjuvant treatment. Psycho-Oncology. 
22(4):936-9 
11 Burris, J.L., Jacobsen P.B., Loftus, L.S., Andrykowski M.A. (2012) Breast cancer recurrence risk reduction 
beliefs in breast cancer survivors: prevalence and relation to behaviour. Psycho-Oncology. 21:427-435 
12 Levesque, C.S., Williams G.C., Elliot D, Pickering M.A., Bodenhamer B, Finley P.J. (2007) Validating the 
theoretical structure of the Treatment Self-Regulation Questionnaire (TSRQ) across three different health 
behaviours. Health Education Research 22(5): 691-702 
13 Devins G.M., Binik Y.M., Hutchinson T.A., Hollomby D.J., Barré P.E. & Guttmann R.D. The emotional 
impact of end-stage renal disease: Importance of patients' perceptions of intrusiveness and control. International 
Journal of Psychiatry in Medicine. 13(4), 1983, pp.327-343. 
14 Hall P.A., Geoffrey T.F., Cheng, A.Y. (2012) Time perspective and weight management behaviors in newly 
diagnosed Type 2 diabetes: a mediational analysis. Journal of Behavioural Medicine. 35(6):569-80. 
15Sniehotta, F F., Schwarzer, R., Scholz, U, Schüz, B.(2005) Action planning and coping planning for long-term 
lifestyle change: theory and assessment. European Journal of Social Psychology. 35, 565-576 
16 Sniehotta, F.F., Nagy G, Scholz U, Schwarzer R.(2006) The role of action control in implementing intentions 
during the first weeks of behaviour change. British Journal of Social Psychology. 45, 87-106 
17 Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of 
medication adherence. Medical Care. 1986;24(1):67-74. 
18 Gardner, B, Abraham C, Lally P & de Bruijn G (2012) Towards parsimony in habit measurement: Testing the 
convergent and predictive validity of an automaticity subscale of the Self-Report Habit Index. International 
Journal of Behavioral Nutrition and Physical Activity, 9:102 DOI: 10.1186/1479-5868-9-102 
  
27 
 
Table 1: Self-reported hormonal therapy non-adherence (Voils scale) per MTB group 
(N=218)  
MTB N (%)* Voils Mean (SD) 
Adherent and persistent 193 (88.53) 1.55 (0.64) 
Non-adherent and persistent 12 (5.50) 2.11 (1.01) 
Non-persistent** 13 (5.96) 2.10 (1.64) 
* Missing data for 5 women 
** Non-persistent women were no longer taking hormonal therapy and reported adherence was in relation to 
when they were taking hormonal therapy (prior to stopping) 
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Table 2: Descriptive statistics for the 8 TDF domains (N=223) 
Domain Construct Measure Average 
inter-item 
correlation  
   
Median (IQR) 
 
Knowledge Action and usage  6 (4, 8) 0.47 
 Potential problems 2  (0, 5)  
 General knowledge  3 (2, 3)  
   
Median (IQR) 
 
Social Influences Support and barriers to MTB 12 (9, 12) 0.18 
 Injunctive norms 7 (6, 7)  
 Descriptive norms 7 (5, 7)  
   
N (%) 
 
Social Identity Support from oncologist (right level) 166 (78) 
 
0.54 
 Support from oncology services - one 
main point of contact/support 
156 (70)  
 Relationship with oncologist-        
listening (yes) 
171 (82)  
 Relationship with oncologist- 
understanding (yes) 
166 (80)  
 Relationship with oncologist-          
respect (yes)  
177 (85)  
 Relationship with oncologist- time (yes)  155 (75) 
 
 
   
Median (IQR) 
 
Beliefs about Capability  Action self-efficacy 10 (9 ,10) 0.35 
 Maintenance self-efficacy 10 (9, 10)  
 Recovery self-efficacy  10 (9, 10)  
 Resilience  4 (3 ,4)  
   
Median (IQR) 
 
Beliefs about 
Consequences 
Perceived severity of breast cancer 9 (8 ,11) 0.16 
 Perceived susceptibility to breast cancer 11 (9, 12)  
 Perceived utility of adhering to hormonal 
therapy 
15 (11, 18)  
 Illness perceptions 9 (7, 10) 
 
 
 Beliefs about hormonal therapy- necessity  16 (14, 18)  
 Beliefs about hormonal therapy- concerns 12 (10, 15)  
 Outcome expectancies- perceived 
outcomes if take/don’t take hormonal 
therapy 
11 (9, 13)  
 Outcome expectancies- perceived cancer 
recurrence risk if take hormonal therapy 
-0.88 (-1.59, 0.04)  
 Outcome expectancies- perceived cancer 
recurrence risk if don’t take hormonal 
therapy 
0.04 (-0.54, 0.75)  
 Concern about breast cancer recurrence 2 (1 , 2)  
   
Median (IQR) 
 
Intentions, Goals and Intention to take hormonal therapy as 14 (14, 14) 0.64 
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Domain Construct Measure Average 
inter-item 
correlation  
Reinforcement prescribed 
 Autonomous motivation 6 (5, 7)  
 Introjected regulation 5 (4, 7)  
 External Regulation 3 (1, 4)  
 Amotivation 3 (2, 4)  
 Adapted Illness Intrusiveness Ratings- 
Physical Well-Being 
2 (0, 3)  
 Adapted Illness Intrusiveness Ratings- 
Work and finances 
1 (0, 4)  
 Adapted Illness Intrusiveness Ratings- 
Martial, sexual and family relationships 
2 (0, 4)  
 Adapted Illness Intrusiveness Ratings- 
Recreation and social relationships 
1 (0, 3)  
 Adapted Illness Intrusiveness Ratings- 
Other aspects of life 
0 (0, 2)  
 Perceived reinforcement and goal conflict 
and facilitation 
2 (2, 3)  
   
Median (IQR) 
 
Behaviour Regulation   
 
Action planning 3 (3, 4) 0.23 
 Coping planning  3 (2, 3)  
 Action control- awareness of standards 3 (2, 3)  
 Action control- self-monitoring 3 (2, 4)  
 Action control- self-regulatory effort 3 (3, 4)  
   
N (%) 
 
Memory, Attention, 
Decision Making and 
Environment 
Forgetting/difficulties remembering to 
take hormonal therapy (No) 
152 (68) 0.27 
 Forgetting/difficulties remembering to get 
prescription refilled (No) 
213 (96)  
 Forgetting/difficulties recalling 
medication usage (No) 
197 (88)  
 Environmental Context- forget when 
travelling or leaving home (No) 
207 (93)  
 Environmental Context- forget when 
interruptions to normal routine (No) 
185 (83)  
   
Median (IQR) 
 
 Habit strength- history of repetition, 
automaticity (lack of control and 
awareness, efficiency) 
3 (3, 4)  
 
 
 
